TTY Biopharm Company Limited

4105

TW0004105002

Pharmaceuticals

End-of-day quote Taipei Exchange Other stock markets 23:00:00 30/05/2024 BST			5-day change	1st Jan Change
77.6 ^TWD	+1.31%		+0.26%	-3.48%

05-30	TTY Biopharm Company Limited Approves Board Appointments	CI
05-30	TTY Biopharm Company Limited Approves Cash Dividend for the Year 2023	CI

TTY Biopharm Company Limited Announces Executive Changes, with Effect from January 20, 2021

November 20, 2020 at 08:12 am

TTY Biopharm Company Limited replaced Tsai Shi-Hua with Hu Yu-Fang as research and development officer with effect from January 20, 2021.

Latest news about TTY Biopharm Company Limited

TTY Biopharm Company Limited Approves Board Appointments	05-30	CI
TTY Biopharm Company Limited Approves Cash Dividend for the Year 2023	05-30	CI
TTY Biopharm Company Limited Announces Chief Financial Officer Changes	05-16	CI
TTY Biopharm Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
TTY Biopharm Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023	03-14	CI
TTY Biopharm Company Limited Announces Change of CFO and Financial Officer	03-08	CI
TTY Biopharm Company Limited Proposes Cash Dividend for the Year Ended December 31, 2023, Payable on April 26, 2024	03-08	CI
TTY Biopharm Company Limited Appoints Peng,Cheng-Yi as Research and Development Officer, Effective February 01, 2024	01-30	CI
TTY Biopharm Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-03	CI
TTY Biopharm Company Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/08/23	CI
TTY Biopharm Company Limited Receives Milestone Payment from German Pharmaceutical Company for Co-Development of Liposome Product-Pegylipo in Europe	09/08/23	CI
TTY Biopharm Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	04/05/23	CI
TTY Biopharm Company Limited Reports Earnings Results for the Full Year Ended December 31, 2022	14/03/23	CI
TTY Biopharm Company Limited Proposes Dividend Distribution for the Year Ended December 31, 2022, Payable on May 5, 2023	14/03/23	CI
Aurobindo Pharma Arm Gets US FDA Nod for Amphotericin B Liposome	18/11/22	MT
TTY Biopharm Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	04/11/22	CI
TTY Biopharm Company Limited Announces Internal Audit Officer Changes, Effective November 7, 2022	04/11/22	CI
TTY Biopharm Company Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	05/08/22	CI
TTY Biopharm Company Limited Announces Dividend Distribution, Payable on August 15, 2022	01/07/22	CI
TTY Biopharm Company Limited Announces Cash Dividend for the Year 2021	26/05/22	CI
TTY Biopharm Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2022	12/05/22	CI
TTY Biopharm Company Limited Announces the Resignation of Chou,Te-Yu as Member of Remuneration Committee	31/03/22	CI
TTY Biopharm Company Limited Proposes Cash Dividend for the Year 2021	09/03/22	CI
TTY Biopharm Company Limited Reports Earnings Results for the Full Year Ended December 31, 2021	08/03/22	CI
TTY Biopharm Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	03/11/21	CI

Chart TTY Biopharm Company Limited

Duration

Period

More charts

TTY Biopharm Co Ltd is a Taiwan-based company mainly engaged in the research, development, manufacture and sale of pharmaceutical preparations. The Company mainly operates through six business segments including Cancer Drug segment, Healthcare segment, Anti-Infective Drug segment, Domestic Cardiovascular and Gastrointestinal Drug segment, Mainland Medical Drug segment and the Other segment. The main products include oncology medicines, anti-infective medicines and health care medicines. Oncology medicines are mainly anti-cancer and auxiliary drugs. Anti-infective medicines are mainly back-line antimicrobial agents and influenza vaccines. Medical and health care medicines are mainly gastrointestinal health care, bone health care, metabolic health care, infection treatment drugs. The Company distributes its products in domestic and overseas markets.

Sector

Pharmaceuticals

Calendar

01/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

77.6 TWD

Average target price

78 TWD

Spread / Average Target

+0.52%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TTY BIOPHARM COMPANY LIMITED	-3.48%	588M
ELI LILLY AND COMPANY	+40.73%	734B
NOVO NORDISK A/S	+32.83%	591B
JOHNSON & JOHNSON	-6.30%	350B
MERCK & CO., INC.	+15.15%	315B
ABBVIE INC.	+4.05%	276B
ASTRAZENECA PLC	+15.00%	238B
NOVARTIS AG	+9.78%	206B
ROCHE HOLDING AG	-5.52%	204B
AMGEN INC.	+6.17%	161B

Other Pharmaceuticals